Copyright © 2021. Inderes Oyj. All rights reserved.

CellaVision

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
20.7.
2021

Redeye views the Q2 from Cellavision this morning as very much in line with our expectations and continued solid recovery story.

Tiedotteet
20.7.
2021

1 April-30 June 2021

  • Net sales increased by 15% to SEK 135.5 million (118.0).
  • Sales increased organically by 23% (-15), currency effect -8%.
  • EBITDA amounted to SEK 47.1 million (36.2).
  • EBITDA margin amounted to 35% (31).
  • Profit before tax amounted to SEK 38.9 million (34.4).
  • Earnings per share before and after dilution were SEK 1.30 (1.14).
  • Cash flow from operating activities amounted to SEK 38.9 million (34.1).


1 January-30 June 2021

Tiedotteet
5.7.
2021

CellaVision AB (publ) will publish the Interim report for the second quarter, on July 20, 2021 at 7:20 CEST.

The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where
Simon Østergaard, President & CEO, will present and comment the report.

Tiedotteet
29.4.
2021

The following resolutions were passed at the annual general meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 29 April 2021. Due to the covid-19 pandemic, CellaVision‘s annual general meeting was carried out through advance voting (postal voting) only.

Muut analyysit
28.4.
2021

Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year.

Tiedotteet
28.4.
2021

1 January-31 March 2021
Net sales were flat versus last year, SEK 134.0 million (134.4).
Sales increased organically by 7% (+1), currency effect -7%
EBITDA amounted to SEK 46.2 million (41.2).
EBITDA margin amounted to 34% (31).
Profit before tax amounted to SEK 35.6 million (25.5).
Earnings per share before and after dilution were SEK 1.19 (0.85).
Cash flow from operating activities amounted to SEK 26.2 million (15.4).

Tiedotteet
20.4.
2021

CellaVision has completed the previously announced acquisition of the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics.

Tiedotteet
15.4.
2021

CellaVision AB (publ) will publish the Interim report for the first quarter, on April 28, 2021 at 8:20 CET. The report will be available at www.cellavision.com

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Simon Østergaard, President & CEO, will present and comment the report.

Tiedotteet
8.4.
2021

Today, CellaVision announced that the company's Annual and Sustainability Report for 2020 is available as PDF at www.cellavision.com and can be read via the link below.

The company has decided to print CellaVisions 2020 Annual and Sustainability Report in a small number of copies in accordance with the company's environmental policy. To request a printed version, please visit the investor pages at CellaVision's website.

Tiedotteet
6.4.
2021

CellaVision announces that the company has signed an agreement to acquire the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics. The acquisition gives CellaVision access and control of an interesting future technology. The acquisition has a cash purchase price of SEK 28,7 million.

CellaVision